MedTrace Logo

Diagnostic Power Comparison Between VOCs and CTCs

NCT03958812 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-06-03

No results posted yet for this study

Summary

Early diagnosis of malignant tumors is pivotal for improving their prognoses. Circulating tumor cells (CTC) in peripheral blood and Volatile organic compounds (VOCs) in exhaled breath are newly developed diagnosis method. Due to the low percentage of CTCs in peripheral blood of cancer patients and the surface structure of lymphocytes (especially megakaryocytes) is often confused with tumor cells, CTC has a high false positive and negative rate. In recent years, the detection of volatile organic compounds (VOCs) in exhaled breath as a simple and noninvasive method has shown broad application prospects in the diagnosis of various diseases. A series of studies of VOCs diagnosing solid tumors the investigators had conducted in the past decade show that VOCs can not only distinguish different types of tumors, but also can make a distinction between different stages. This study was to compare CTC and VOCs with clinical samples. Predictive models will be built employing discriminant factor analysis (DFA) pattern recognition method. Sensitivity and specificity will be determined using leave-one-out cross-validation or an independent blind test set.

Conditions

Interventions

DIAGNOSTIC_TEST

Circulating tumor cells, Volatile organic compounds

Alveolar exhaled breath samples and peripheral venous blood(10ml) will be collected from each patients

Sponsors & Collaborators

  • Technion, Israel Institute of Technology

    collaborator OTHER

  • Anhui Medical University

    lead OTHER

Principal Investigators

  • Hu Liu, MD · Anhui Provincial Cancer Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-15
Primary Completion
2020-06-01
Completion
2020-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03958812 on ClinicalTrials.gov